126 related articles for article (PubMed ID: 6305854)
1. Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
Béchet JM; Guétard D
Int J Cancer; 1983 Jul; 32(1):61-5. PubMed ID: 6305854
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of enhancement of Epstein-Barr virus-induced transformation of peripheral blood lymphocytes by a tumor promoter, TPA, with special reference to lowering of cytotoxicity of T cells.
Harada S; Katsuki T; Yamamoto H; Hinuma Y
Int J Cancer; 1981 May; 27(5):617-23. PubMed ID: 6270019
[TBL] [Abstract][Full Text] [Related]
3. Interactions between Epstein-Barr virus (EBV) and human cell lines: growth and EBV induction.
Takimoto T; Iwawaki J; Tanaka S; Umeda R
ORL J Otorhinolaryngol Relat Spec; 1990; 52(1):40-6. PubMed ID: 2154734
[TBL] [Abstract][Full Text] [Related]
4. Tumour-promoting phorbol esters inhibit DNA synthesis and enhance virus-induced interferon production in a human lymphoma cell line.
Adolf GR; Swetly P
J Gen Virol; 1980 Nov; 51(Pt 1):61-7. PubMed ID: 6161998
[TBL] [Abstract][Full Text] [Related]
5. Induction of Epstein-Barr virus by an new tumor promoter, teleocidin, compared to induction by TPA.
Yamamoto H; Katsuki T; Hinuma Y; Hoshino H; Miwa M; Fujiki H; Sugimura T
Int J Cancer; 1981 Aug; 28(2):125-9. PubMed ID: 6274809
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus type 1 infection of isogenic Epstein-Barr virus genome-negative and -positive Burkitt's lymphoma-derived cell lines.
Leinbach SS; Summers WC
J Virol; 1979 Apr; 30(1):248-54. PubMed ID: 225521
[TBL] [Abstract][Full Text] [Related]
7. Conversion of the lymphoma line "BJAB" by Epstein-Barr virus into phenotypically altered sublines is accompanied by increased c-myc mRNA levels.
Wennborg A; Aman P; Saranath D; Pear W; Sümegi J; Klein G
Int J Cancer; 1987 Aug; 40(2):202-6. PubMed ID: 3038758
[TBL] [Abstract][Full Text] [Related]
8. Molecular size variation of EBNA is determined by the EB viral genome.
Gergely L; Sternås L; Dillner J; Klein G
Intervirology; 1984; 22(2):85-96. PubMed ID: 6090339
[TBL] [Abstract][Full Text] [Related]
9. Tumor promoter 12-O-tetradecanoylphorbol 13-acetate: effect on complement and Epstein-Barr virus receptors in human lymphoblastoid cell lines.
Yamamoto N; Mitsuma T; Vogt A
J Natl Cancer Inst; 1982 Mar; 68(3):385-90. PubMed ID: 6278193
[TBL] [Abstract][Full Text] [Related]
10. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of outgrowth of EB virus-transformed cells from normal human peripheral blood by a tumor promoter, TPA.
Yamamoto H; Katsuki T; Harada S; Hinuma Y
Int J Cancer; 1981 Feb; 27(2):161-6. PubMed ID: 6270011
[TBL] [Abstract][Full Text] [Related]
12. Hexose transport in Epstein-Barr virus (EBV) negative lymphoma lines and their EBV converted, virus genome carrying sublines.
Siegert W; Mönch T
Blut; 1981 Nov; 43(5):297-305. PubMed ID: 6275931
[TBL] [Abstract][Full Text] [Related]
13. Steroids inhibit tumor promoting agent induced Epstein-Barr virus early antigens in Raji cells.
Sundar SK; Ablashi DV; Armstrong GR; Zipkin M; Faggioni A; Levine PH
Int J Cancer; 1981 Oct; 28(4):503-7. PubMed ID: 6273335
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two ebv-negative lymphoma lines and their EBV-converted sublines.
Ernberg I; Klein G; Giovanella BC; Stehlin J; McCormick KJ; Andersson-Anvret M; Aman P; Killander D
Int J Cancer; 1983 Feb; 31(2):163-9. PubMed ID: 6298125
[TBL] [Abstract][Full Text] [Related]
15. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Fresen KO; Hausen H
Int J Cancer; 1976 Feb; 17(2):161-6. PubMed ID: 175026
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
Fresen KO; Cho MS; zur Hausen H
Int J Cancer; 1978 Aug; 22(2):160-5. PubMed ID: 81181
[TBL] [Abstract][Full Text] [Related]
17. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.
Klein G; Zeuthen J; Terasaki P; Billing R; Honig R; Jondal M; Westman A; Clements G
Int J Cancer; 1976 Nov; 18(5):639-52. PubMed ID: 62724
[TBL] [Abstract][Full Text] [Related]
18. Cell surface glycoprotein patterns of two EBV-negative lines and their EBV converted sublines.
Koide N; Wells A; Klein G; Ernberg I
Intervirology; 1981; 16(3):142-8. PubMed ID: 6277822
[TBL] [Abstract][Full Text] [Related]
19. Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation.
Anisimová E; Prachová K; Roubal J; Vonka V
Arch Virol; 1984; 81(3-4):223-37. PubMed ID: 6089703
[TBL] [Abstract][Full Text] [Related]
20. Tumour promoter TPA enhances transformation of human leukocytes by Epstein-Barr virus.
Yamamoto N; zur Hausen H
Nature; 1979 Jul; 280(5719):244-5. PubMed ID: 221841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
